Henry N Ginsberg

Q: What Schools Are Affiliated With Henry N Ginsberg

Henry N Ginsberg is affiliated with the following schools: California Institute of Technology, SUNY Downstate Medical Center, Icahn School of Medicine at Mount Sinai, Stanford University, University of Washington, Columbia University

Henry N Ginsberg's AcademicInfluence.com Rankings

Henry N Ginsberg

Engineering

#2914

World Rank

#3911

Historical Rank

Cybernetics

#31

World Rank

#35

Historical Rank

Biomedical Engineering

#105

World Rank

#107

Historical Rank

Applied Physics

#449

World Rank

#467

Historical Rank

engineering Degrees

Henry N Ginsberg

Biology

#5580

World Rank

#8094

Historical Rank

Bioinformatics

#55

World Rank

#56

Historical Rank

Computational Biology

#89

World Rank

#89

Historical Rank

biology Degrees

Download Badge

Engineering
Biology

Henry N Ginsberg's Degrees

PhD Biomedical Engineering Stanford University
Masters Biomedical Engineering Stanford University
Bachelors Biomedical Engineering Stanford University

Why Is Henry N Ginsberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Henry N Ginsberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guidelines for the use and interpretation of assays for monitoring autophagy (2012) (6925)
Effects of combination lipid therapy in type 2 diabetes mellitus. (2010) (2425)
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. (1988) (1962)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) (1817)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) (1786)
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. (2011) (1543)
Lipoprotein(a) as a cardiovascular risk factor: current status (2010) (1466)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011) (1099)
Effects of medical therapies on retinopathy progression in type 2 diabetes. (2010) (1073)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) (980)
Long-term effects of intensive glucose lowering on cardiovascular outcomes. (2011) (950)
Low-density lipoproteins cause atherosclerotic cardiovascular disease (2018) (936)
The prevention or delay of type 2 diabetes. (2002) (727)
Insulin resistance and cardiovascular disease. (2000) (635)
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2007) (587)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) (545)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) (541)
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. (2007) (530)
Regulation of plasma triglycerides in insulin resistance and diabetes. (2005) (478)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. (2008) (473)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) (470)
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia (2015) (467)
Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* (2002) (453)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. (2014) (442)
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. (2008) (436)
Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. (2014) (394)
Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. (1991) (386)
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. (2007) (371)
The apolipoprotein ε4 allele in patients with Alzheimer's disease (1993) (369)
Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) (356)
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. (2008) (352)
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia (1997) (351)
Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. (1993) (347)
Triglyceride, high density lipoprotein, and coronary heart disease. (1993) (335)
Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. (2005) (328)
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance (2011) (312)
5. Prevention or Delay of Type 2 Diabetes (2016) (311)
The Degradation of Apolipoprotein B100 Is Mediated by the Ubiquitin-proteasome Pathway and Involves Heat Shock Protein 70* (1997) (304)
Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis (1991) (300)
Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. (1998) (283)
C-C Chemokine Receptor 2 (CCR2) Regulates the Hepatic Recruitment of Myeloid Cells That Promote Obesity-Induced Hepatic Steatosis (2010) (277)
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. (2018) (276)
Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. (2004) (272)
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia (2001) (267)
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients (2008) (261)
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism (2002) (259)
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. (2009) (252)
Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. (1975) (251)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. (2014) (249)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study (2018) (244)
CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status (2012) (242)
Role of Cardiovascular Risk Factors in Prevention and Treatment of Macrovascular Disease in Diabetes (1989) (240)
Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. (1982) (239)
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. (2007) (234)
Acute Elevations of Plasma Asymmetric Dimethylarginine and Impaired Endothelial Function in Response to a High-Fat Meal in Patients With Type 2 Diabetes (2000) (230)
Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. (1993) (223)
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract (2018) (221)
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk (2017) (216)
The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis (2000) (216)
Reduction of plasma cholesterol levels in normal men on an American Heart Association Step 1 diet or a Step 1 diet with added monounsaturated fat. (1990) (207)
Metabolic Syndrome: Focus on Dyslipidemia (2006) (205)
Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health. (2010) (200)
Clinical review on triglycerides (2019) (194)
Metabolism of Cholesterol and Plasma Triglycerides in Nonketotic Diabetes Mellitus (1982) (189)
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). (2014) (187)
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. (1987) (183)
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. (2015) (180)
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans (2017) (171)
Diabetic Dyslipidemia: Basic Mechanisms Underlying the Common Hypertriglyceridemia and Low HDL Cholesterol Levels (1996) (169)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher (2016) (167)
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus (2005) (164)
Lipoprotein metabolism and its relationship to atherosclerosis. (1994) (162)
Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. (2000) (157)
Lipoprotein physiology. (1998) (157)
Residual macrovascular risk in 2013: what have we learned? (2014) (157)
Regulated Co-translational Ubiquitination of Apolipoprotein B100 (1998) (156)
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. (2007) (153)
Special Report Rationale of the Diet‐Heart Statement of the American Heart Association Report of the Nutrition Committee (1993) (147)
Aberrant Hepatic Expression of PPARγ2 Stimulates Hepatic Lipogenesis in a Mouse Model of Obesity, Insulin Resistance, Dyslipidemia, and Hepatic Steatosis* (2006) (145)
Moderate ethanol ingestion and plasma triglyceride levels. A study in normal and hypertriglyceridemic persons. (1974) (141)
REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. (2006) (139)
Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. (2014) (138)
A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. (1994) (138)
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability (2013) (137)
Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. (1995) (137)
Dehydroepiandrosterone Feeding Prevents Aortic Fatty Streak Formation and Cholesterol Accumulation in Cholesterol‐fed Rabbit (1989) (137)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies (2016) (133)
Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. (1994) (130)
Metabolism of plasma triglycerides in hypothyroidism and hyperthyroidism in man. (1981) (127)
Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. (1996) (124)
Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. (2005) (123)
Overexpression of the Tumor Autocrine Motility Factor Receptor Gp78, a Ubiquitin Protein Ligase, Results in Increased Ubiquitinylation and Decreased Secretion of Apolipoprotein B100 in HepG2 Cells* (2003) (122)
Proteolysis and lipid-facilitated translocation are distinct but competitive processes that regulate secretion of apolipoprotein B in Hep G2 cells. (1993) (122)
Studies of the sites of intracellular degradation of apolipoprotein B in Hep G2 cells. (1992) (121)
Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester. (1994) (118)
Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence. (1998) (118)
Treatment for patients with the metabolic syndrome. (2003) (115)
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) (115)
Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants (2012) (113)
Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. (2008) (108)
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes (2017) (108)
Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial (2014) (104)
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study (2016) (104)
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial (2019) (103)
Induction of hypertriglyceridemia by a low-fat diet. (1976) (102)
Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. (2012) (101)
Effect of Insulin Therapy on Insulin Resistance in Type II Diabetic Subjects: Evidence for Heterogeneity (1981) (101)
Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity. (1981) (100)
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. (2014) (99)
Overexpression of Human Diacylglycerol Acyltransferase 1, Acyl-CoA:Cholesterol Acyltransferase 1, or Acyl-CoA:Cholesterol Acyltransferase 2 Stimulates Secretion of Apolipoprotein B-containing Lipoproteins in McA-RH7777 Cells* (2004) (98)
Combined lipase deficiency (cld): a lethal mutation on chromosome 17 of the mouse. (1983) (98)
Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women. (1995) (97)
The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk (2003) (95)
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. (2001) (94)
Co-translational Interactions of Apoprotein B with the Ribosome and Translocon during Lipoprotein Assembly or Targeting to the Proteasome* (2001) (93)
Further Evidence that Insulin Resistance Exists in Patients with Chemical Diabetes (1974) (93)
Regulation of Hepatic Apolipoprotein B-lipoprotein Assembly and Secretion by the Availability of Fatty Acids (2004) (91)
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. (2007) (91)
Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity‐related insulin resistance (2001) (91)
Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. (2006) (90)
Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low‐density lipoprotein cholesterol concentrations (1986) (89)
The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue. (2014) (88)
Biosynthesis of lipoproteins (2000) (87)
Effects of statins on triglyceride metabolism. (1998) (87)
Personalized glucose forecasting for type 2 diabetes using data assimilation (2017) (86)
Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes (2017) (85)
Reductions in Atherogenic Lipids and Major Cardiovascular Events (2016) (85)
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential (2019) (84)
A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering (1999) (83)
Synthesis and secretion of apolipoprotein B from cultured liver cells (1995) (82)
Low rates of apoB secretion from HepG2 cells result from reduced delivery of newly synthesized triglyceride to a "secretion-coupled" pool. (1996) (81)
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. (2020) (81)
Chronic alcohol consumption decreases brown adipose tissue mass and disrupts thermoregulation: a possible role for altered retinoid signaling (2017) (80)
HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. (1999) (80)
Lipoprotein metabolism in chronic renal insufficiency (2007) (79)
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. (2020) (79)
Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease (2020) (78)
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. (2005) (78)
Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy (2011) (78)
Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre- and post-translational mechanisms. (1994) (78)
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study (2016) (78)
Post-transcriptional Stimulation of the Assembly and Secretion of Triglyceride-rich Apolipoprotein B Lipoproteins in a Mouse with Selective Deficiency of Brown Adipose Tissue, Obesity, and Insulin Resistance* (2001) (77)
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle[S] (2011) (73)
Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. (2008) (73)
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial (2011) (72)
Association of plasma lipoproteins with postheparin lipase activities. (1986) (71)
Posttranscriptional Control of the Expression and Function of Diacylglycerol Acyltransferase-1 in Mouse Adipocytes* (2002) (70)
Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council (2015) (70)
The Late Addition of Core Lipids to Nascent Apolipoprotein B100, Resulting in the Assembly and Secretion of Triglyceride-rich Lipoproteins, Is Independent of Both Microsomal Triglyceride Transfer Protein Activity and New Triglyceride Synthesis* (2002) (69)
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. (2021) (68)
Radiotracers for low density lipoprotein biodistribution studies in vivo: technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. (1988) (67)
The role of acyl‐CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism (2004) (67)
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices (2011) (66)
Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. (2001) (64)
CCR 5 Plays a Critical Role in Obesity-Induced Adipose Tissue In fl ammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M 1 / M 2 Status (2012) (64)
Diabetic dyslipidemia. (2006) (63)
Apolipoprotein CIII: 42 years old and even more interesting. (2011) (63)
Indium-111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. (1990) (63)
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying (2012) (61)
Lipoprotein physiology and its relationship to atherogenesis. (1990) (61)
Cardiomyocyte-specific Loss of Diacylglycerol Acyltransferase 1 (DGAT1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure* (2014) (58)
Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease (1984) (58)
Metabolic effects of increased caloric intake in man. (1975) (57)
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data (2017) (57)
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience (2012) (57)
The Conversion of ApoB100 Low Density Lipoprotein/High Density Lipoprotein Particles to ApoB100 Very Low Density Lipoproteins in Response to Oleic Acid Occurs in the Endoplasmic Reticulum and Not in the Golgi in McA RH7777 Cells* (2003) (57)
Is Hypertriglyceridemia a Risk Factor for Atherosclerotic Cardiovascular Disease? A Simple Question with a Complicated Answer (1997) (55)
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. (2019) (54)
Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management (2002) (52)
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism (2019) (52)
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era (2015) (51)
Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial (2013) (51)
CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects (2017) (51)
Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue. (2005) (51)
The metabolism of lipoprotein (a): an ever-evolving story (2017) (50)
Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients (1994) (50)
Hepatic synthesis of lipoproteins and apolipoproteins. (1992) (50)
Very low density lipoprotein metabolism in diabetes mellitus. (1987) (49)
The Amino-terminal Domain of Apolipoprotein B Does Not Undergo Retrograde Translocation from the Endoplasmic Reticulum to the Cytosol (2000) (48)
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. (2022) (48)
Microsomal Triglyceride Transfer Protein Binding and Lipid Transfer Activities Are Independent of Each Other, but Both Are Required for Secretion of Apolipoprotein B Lipoproteins from Liver Cells* (2001) (48)
Progress and perspectives in plant sterol and plant stanol research (2018) (47)
Investigation of insulin resistance during diabetic ketoacidosis: role of counterregulatory substances and effect of insulin therapy. (1977) (47)
Nonpharmacologic management of low levels of high-density lipoprotein cholesterol. (2000) (47)
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus (2011) (46)
Adipose tissue distribution after weight restoration and weight maintenance in women with anorexia nervosa. (2009) (46)
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective (2011) (45)
ROLE OF LIPID SYNTHESIS, CHAPERONE PROTEINS AND PROTEASOMES IN THE ASSEMBLY AND SECRETION OF APOPROTEIN B‐CONTAINING LIPOPROTEINS FROM CULTURED LIVER CELLS (1997) (45)
Quantification of plasma cholesterol and triglyceride levels in hypercholesterolemic subjects receiving ascorbic acid supplements. (1975) (45)
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes (2017) (44)
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. (2016) (44)
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. (2020) (44)
Diabetes and dyslipidemia. (2001) (44)
Human plasma LDL cryopreserved with sucrose maintains in vivo kinetics indistinguishable from freshly isolated human LDL in cynomolgus monkeys. (1994) (43)
Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue (2014) (43)
Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol? (2006) (43)
Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism[S] (2011) (42)
ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. The DELTA Research Group. Dietary Effects on Lipoproteins and Thrombogenic Activity. (1997) (41)
Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. (1998) (39)
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia Published, JLR Papers in Press, September 14, 2005. DOI 10.1194/jlr.M500335-JLR200 (2005) (39)
Noninvasive imaging of 99mtechnetium-labeled low density lipoprotein uptake by tendon xanthomas in hypercholesterolemic patients. (1990) (39)
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. (2015) (38)
Apolipoprotein B Secretion Is Regulated by Hepatic Triglyceride, and Not Insulin, in a Model of Increased Hepatic Insulin Signaling (2012) (37)
Predictors of postprandial triacylglycerol response in children: the Columbia University Biomarkers Study. (2000) (37)
Gerald M. Reaven, MD: Demonstration of the Central Role of Insulin Resistance in Type 2 Diabetes and Cardiovascular Disease (2014) (36)
LPL promoter -93T/G transition influences fasting and postprandial plasma triglycerides response in African-Americans and Hispanics. (1998) (36)
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. (2019) (36)
Nuclear envelope-localized torsinA-LAP1 complex regulates hepatic VLDL secretion and steatosis. (2019) (35)
Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects[S] (2018) (35)
Hypocholesterolemia as a manifestation of disease activity in chronic myelocytic leukemia (1983) (33)
Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans (2016) (32)
Age-related effects of genetic variation on lipid levels: The Columbia University BioMarkers Study. (2001) (32)
Inhibition of apolipoprotein B synthesis stimulates endoplasmic reticulum autophagy that prevents steatosis. (2016) (31)
Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat* (2016) (30)
Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins. (2014) (30)
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. (1987) (30)
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. (2013) (30)
Increased Catabolism of Native and Cyclohexanedione‐Modified Low Density Lipoprotein in Subjects with Myeloproliferative Diseases (1983) (30)
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study (2021) (30)
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein (2016) (30)
Niacin: a long history, but a questionable future (2013) (29)
Translocation Efficiency of Apolipoprotein B Is Determined by the Presence of β-Sheet Domains, Not Pause Transfer Sequences* (2006) (29)
Treatment of common lipoprotein disorders. (1984) (29)
Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial Trial (2013) (28)
Inhibition of translocation of nascent apolipoprotein B across the endoplasmic reticulum membrane is associated with selective inhibition of the synthesis of apolipoprotein B. (2000) (27)
Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia (2010) (27)
Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene. (1997) (27)
The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia (2009) (26)
Monotherapy with the PCSK 9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia : Results of a 24 week , double-blind , randomized Phase 3 trial (2014) (26)
Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease (1999) (24)
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes (2018) (24)
Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. (2010) (24)
Dietary 1,3-diacylglycerol protects against diet-induced obesity and insulin resistance. (2007) (23)
Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus1 (2009) (23)
Evaluation of Insulin Resistance in Patients with Primary Hyperparathyroidism (1975) (23)
Effects of increasing dietary polyunsaturated fatty acids within the guidelines of the AHA step 1 diet on plasma lipid and lipoprotein levels in normal males. (1994) (23)
Statins in cardiometabolic disease: what makes pitavastatin different? (2013) (22)
Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial (2014) (22)
Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine (2020) (21)
Niacin in the metabolic syndrome: more risk than benefit? (2006) (21)
Hypertriglyceridemia—Causes, Significance, and Approaches to Therapy (2020) (21)
Lipoprotein (a): Coming of Age at Last (2016) (21)
Static and turnover kinetic measurement of protein biomarkers involved in triglyceride metabolism including apoB48 and apoA5 by LC/MS/MS[S] (2014) (20)
Effects of triacylglycerol and diacylglycerol oils on blood clearance, tissue uptake, and hepatic apolipoprotein B secretion in mice Published, JLR Papers in Press, February 3, 2007. (2007) (20)
Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone* (2015) (20)
Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies (2018) (19)
FoxO transcription factors are required for hepatic HDL cholesterol clearance (2018) (19)
Increased production rates of LDL are common in individuals with low plasma levels of HDL cholesterol, independent of plasma triglyceride concentrations. (1993) (19)
Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment (2015) (19)
Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus (2011) (19)
Demonstration of biphasic effects of docosahexaenoic acid on apolipoprotein B secretion in HepG2 cells. (1997) (19)
The 2013 ACC/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions. (2014) (19)
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E[S] (2017) (19)
Low-density lipoprotein (LDL) distribution shown by 99mtechnetium-LDL imaging in patients with myeloproliferative diseases. (1989) (18)
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid (2020) (18)
Effects of a 1,3-diacylglycerol oil-enriched diet on postprandial lipemia in people with insulin resistance Published, JLR Papers in Press, December 18, 2007. (2008) (18)
Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome (2021) (17)
Very low density lipoprotein metabolism in non-ketotic diabetes mellitus: Effect of dietary restriction (1982) (17)
Abstract 17070: Efficacy and Safety of Alirocumab: Pooled Analyses of 1048 Individuals With Diabetes Mellitus From Five Placebo-controlled Phase 3 Studies of at Least 52 Weeks Duration (2015) (17)
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials (2018) (16)
Autophagy and cardiometabolic risk factors (2014) (16)
γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. (2018) (15)
Circulating Lipoprotein Profiles are Modulated Differently by Lipoprotein Lipase in Obese Humans (2000) (15)
High-density lipoprotein cholesterol is reduced in patients with sarcoidosis. (1989) (15)
Increased erythrocyte susceptibility to lipid peroxidation in myeloproliferative disorders. (1984) (15)
Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study (2017) (15)
32 TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE: EVIDENCE AND GUIDANCE FOR MANAGEMENT (2011) (15)
New directions in dietary studies and heart disease: the National Heart, Lung and Blood Institute sponsored Multicenter Study of Diet Effects on Lipoproteins and Thrombogenic Activity. (1995) (15)
Diagnosis of acute cholecystitis by cholescintigraphy: significance of pericholecystic hepatic uptake. (1989) (14)
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials (2016) (14)
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. (2019) (14)
Impaired postprandial lipemic response in chronic kidney disease. (2016) (14)
Preparedness of the CTSA's Structural and Scientific Assets to Support the Mission of the National Center for Advancing Translational Sciences (NCATS) (2012) (14)
Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes (2018) (13)
Haptoglobin Phenotype Modifies the Influence of Intensive Glycemic Control on Cardiovascular Outcomes. (2020) (13)
Ovariectomy leads to increased insulin resistance in human apolipoprotein B transgenic mice lacking brown adipose tissue. (2003) (13)
No effect of PCSK 9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies (2016) (13)
Diabetes and dyslipidemia (2001) (12)
Bilateral temporal bone involvement with eosinophilic granuloma. (1988) (12)
Medical complications of isotretinoin. (1986) (12)
Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling (2016) (12)
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia (2019) (12)
Hypercalcemia and Complete Heart Block (1973) (12)
Clinical syndrome and lipid metabolism in hereditary deficiency of apolipoproteins A-I and C-III, variant 1. (1986) (11)
Understanding Interdisciplinary Health Sciences Collaborations: A Campus-Wide Survey of Obesity Experts (2008) (11)
Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet. (2012) (11)
Update on the treatment of hypercholesterolemia, with a focus on hmg‐coa reductase inhibitors and combination regimens (1995) (11)
Diet and the decrease of coronary heart disease. (1984) (11)
Variation in the human ApoB signal peptide modulates ApoB17 translocation. (2001) (11)
Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials (2018) (10)
LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials (2021) (10)
ApoB SURFs a Ride from the ER to the Golgi. (2021) (9)
EFFECT OF PRAVASTATIN IN THE TREATMENT OF PATIENTS WITH TYPE III HYPERLIPOPROTEINEMIA (1996) (9)
AHA Scientific Statement Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association (2011) (9)
Diagnosis and Treatment of Lipid Disorders (2005) (9)
Case Report: Transient Lipoprotein Lipase Deficiency with Hyperchylomicronemia (1983) (9)
The Endocannabinoid System: Potential for Reducing Cardiometabolic Risk (2009) (9)
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial (2021) (9)
Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice (2021) (9)
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results. (2008) (8)
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial (2021) (8)
Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/kexin Type 9: Therapeutic Dosing in Phase 3 Studies (2013) (8)
A 24-WEEK STUDY OF ALIROCUMAB AS MONOTHERAPY VERSUS EZETIMIBE: THE FIRST PHASE 3 DATA OF A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR (2014) (8)
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins (2022) (7)
Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen (2010) (7)
Syndrome X: what's old, what's new, what's etiologic? (1993) (7)
Very low-density lipoprotein metabolism in an unusual case of lipoatrophic diabetes. (1984) (7)
8 – Compartmental Models for the Study of Apoprotein B Catabolism in Man (1982) (6)
AHA Conference Report on Cholesterol. Basis for dietary treatment. (1989) (6)
Nutrition and therapeutics: where we are and where we should be going. (1995) (6)
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy. (2022) (6)
Lipoproteins as risk factors for vascular disease in diabetes. (1982) (6)
Pneumoretroperitoneum secondary to hydrogen peroxide wound irrigations. (1987) (6)
Abstract 16863: Alirocumab Effect on Glycemic Measures in Patients Without Diabetes at Baseline (2015) (6)
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus? (2019) (6)
Commentary on 'ApoC-III ASO Promotes Tissue LPL Activity in Absence of apoE-Mediated TRL Clearance". (2019) (5)
The effect of chronic hypocholesterolemia in myeloproliferative disease on the distribution of plasma and erythrocyte tocopherol. (1984) (5)
Mellitus: A Scientific Statement From the American Heart Association and the Primary Prevention of Cardiovascular Diseases in People With Diabetes (2007) (5)
triglyceride levels in hypercholesterolemic subjects receiving ascorbic acid supplements1' 2, 3 (1975) (5)
1.P.230 Variations in the human apolipoprotein B signal peptide alter apoB secretion and degradation in McArdle RH-7777 rat hepatoma cells (1997) (5)
Postprandial response to a physiologic caloric load in HIV-positive patients receiving protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. (2005) (5)
Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, Reduces High Plasma Lp(a) Concentration: Pooled Analysis of 352 Patients from Phase 2 (2013) (5)
Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation (2016) (4)
Risk factors common to insulin resistance and atherosclerosis explain why diabetes is a cardiovascular disease. (2002) (4)
Life is complicated: so is apoCIII1 (2019) (4)
New insights into the regulation of lipoprotein metabolism: studies in procaryocytes, eukaryocytes, rodents, pigs, and people. (1997) (4)
Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks (2014) (4)
Abstract 18484: Modest Potential Association Between Reductions in Lipoprotein(a) and Major Adverse Cardiovascular Events in the Phase 3 Trials of Alirocumab versus Control (2016) (4)
The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials. (2020) (3)
Abstract 17736: Cardiomyocyte Specific Loss of Diacylglycerol Acyl Transferase 1 (Dgat1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure (2014) (3)
Cholesterol management: targeting a lower low-density lipoprotein cholesterol concentration increases adult treatment panel-III goal attainment. (2006) (3)
Abstract 18390: Effects of a Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Healthy Subjects (2015) (3)
The year in cardiovascular medicine 2021: dyslipidaemia. (2022) (3)
Glucose does not stimulate apoprotein B secretion from HepG2 cells because of insufficient stimulation of triglyceride synthesis. (1998) (3)
Insulin Resistance and Dyslipidemia (2008) (3)
Abstract 19724: Hypertriglyceridemia and Low HDL-C Predicts Fenofibrate Response in The ACCORD-Lipid Trial (2010) (3)
Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443) (2012) (3)
Abstract 16127: Effect of REGN727/SAR236553 Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Fully Human Monoclonal Antibody in Patients with Elevated Triglycerides/Low High-Density Lipoprotein Cholesterol: Data from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443) (2012) (3)
Cyclosporine, plasma lipids, and organ transplantation (1996) (3)
Evaluation of 99mTc-LDL for studying lipoprotein metabolism and imaging atherosclerotic lesions in vivo (1985) (3)
Workshop III Basis for Dietary Treatment Participants (2005) (3)
Reply to 'Dyslipidemia due to retroviral protease inhibitors' (2002) (2)
Transient lipoprotein lipase deficiency with hyperchylomicronemia. (1983) (2)
Different fatty acids inhibit apolipoprotein B 100 secretion by different pathways : Unique roles for endoplasmic reticulum stress , ceramide , and autophagy (2011) (2)
Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3) (2022) (2)
CHAPTER 37 – Special Patient Populations: Diabetes and Metabolic Syndrome (2009) (2)
RELATIONSHIP BETWEEN MAJOR ADVERSE CARDIOVASCULAR EVENTS AND ACHIEVED LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN PHASE 3 ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL (2016) (2)
Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort (2023) (2)
PERSPECTIVE SERIES On diabetes : insulin resistance (2000) (2)
Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials (2021) (2)
Three-phase bone scanning in chronic myelogenous leukemia. (1987) (2)
Abstract 15997: The Effect of Combined Statin/Fibrate Therapy on Cardiovascular Disease is Influenced by Sex and Dyslipidemia: ACCORDION-Lipid Long-Term Follow-up (2015) (2)
Monthly haemostatic factor variability in women and men (2014) (2)
Potential false-positive red blood cell gastrointestinal bleeding study secondary to osseous metastasis. (1991) (2)
Treatment with mipomersen reduces levels of apoB-containing lipoproteins by increasing fractional removal of VLDL and LDL-apoB without reducing vldl-apob secretion (2014) (2)
2.P.38 Long-term effects of low dose Omacor® in patients with severe hypertriglyceridemia (1997) (2)
Regulation of hepatic secretion of lipoproteins (1994) (1)
IDF21-0058 The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized trials (2022) (1)
RELATIONSHIP BETWEEN PERCENTAGE REDUCTION IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AMONG PATIENTS TREATED WITH STATINS +/- ALIROCUMAB OR EZETIMIBE IN THE PHASE 3 ODYSSEY TRIALS (2016) (1)
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease (2022) (1)
The Prove It Study: Is It Really a Landmark Study or Another Piece of a Very Important Puzzle? (2004) (1)
Monthly hemostatic factor variability in women and men (2014) (1)
Selective Trafficking of Fatty Acids in the Liver: Add Them2 to the List of Influencers (2019) (1)
Chapter 11. Dyslipoproteinemias in Thyroid Disease (1989) (1)
Effects of the PPARg agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus (2018) (1)
TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut‐liver crosstalk (2022) (1)
BET PROTEIN INHIBITION AND COGNITION: A PRE-SPECIFIED SUBSTUDY OF THE BETONMACE PHASE 3 TRIAL EVALUATING APABETALONE IN PATIENTS WITH DIABETES AND ACUTE CORONARY SYNDROME (2019) (1)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN VERY HIGH RISK PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ANALYSES FROM THE ODYSSEY TRIALS (2017) (1)
Hypocholesterolemia in myeloproliferative diseases with myelofibrosis. (1984) (1)
Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years. (2019) (1)
Abstract 118: The Effect of CETP Inhibition With Anacetrapib on the Metabolism of PCSK9 (2013) (1)
Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?1 (2011) (1)
Treatment of Triglyceride and Cardiovascular Risk (2000) (1)
Lipid metabolism: new approaches to old problems. (1998) (1)
Hyperlipidemia, Diabetes, and the Heart (2002) (1)
Letter: Hypercalcemia and complete heart block. (1973) (1)
The Role of Hepatic Triglyceride Lipase in Primates (1983) (1)
Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial. (2021) (1)
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides (2021) (1)
Abstract 13189: Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study (2018) (1)
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins (2022) (1)
Faculty Opinions recommendation of Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. (2008) (0)
Abstract 20114: Effect of Fenofibrate Therapy on Cardiovascular Disease in Men versus Women with Type 2 Diabetes in the ACCORD-Lipid Trial (2010) (0)
Dyrk1b Displaces Fkbp12 from mTORC2, Causes its Activation and Triggers De Novo Lipogenesis: Implications for the Treatment of Diet-Induced Fatty Liver Disease (2020) (0)
Impact of IMPACT: Longitudinal Analysis of an Integrated Participant Scheduling System in a Clinical Research Setting (2020) (0)
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals (2015) (0)
Very low density lipoproteins and oleic acid stimulate secretion of apoprotein B-containing lipoproteins from HEPG2 cells by different mechanisms (1993) (0)
Dyslipidemia of insulin resistance syndrome explained; need for treatment to reduce risk emphasized. (2002) (0)
Intestinal DGAT 1 defi ciency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying Gene (2012) (0)
University of Dundee Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia (2017) (0)
The JLR opens up its heart (and liver, fat, muscle) to patient-oriented research (2006) (0)
Faculty Opinions recommendation of Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. (2009) (0)
Mo-W3:3 VLDL secretion and catabolism in insulin resistance and type 2 diabetes mellitus (2006) (0)
Mipomersen treatment decreases lipoprotein (a) plasma levels by increasing its fractional clearance from plasma. (2017) (0)
Abstract 506: Hepatic Insulin Signaling Regulates ApoAI Expression Through Type I Deiodinase (2012) (0)
Faculty Opinions recommendation of Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E. (2008) (0)
Abstract 14307: Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial (2020) (0)
Moderate Ethanol Ingestion and Plasma Triglyceride Levels (2020) (0)
Unusual collateral venous blood flow following surgical repair of a thoracic aortic dissection. (1991) (0)
Abstract P182: Recombinant Human Lecithin-cholesterol Acyltransferase Treatment In Patients With ASCVD Increases HDL Through Increases In Cholesterol Ester Content. (2021) (0)
ADVANCES IN THE MANAGEMENT OF DYSLIPIDEMIA IN THE PATIENT WITH DIABETES: CLINICAL CHALLENGES OF SYNDROME X (2001) (0)
The Pancreas and Lipoprotein Metabolism (2011) (0)
Iconographies supplémentaires de l'article : Nonpharmacologic management of low levels of high-density lipoprotein cholesterol (2011) (0)
A phase III multicentre, double-blind, placebo-controlled study (TANGO) to evaluate CER-001 on carotid atherosclerosis (vessel wall area) in patients with familial primary hypoalphalipoproteinaemia (2016) (0)
Abstract 129: Effects of a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, Alirocumab, on Lipid and Lipoprotein Metabolism in Normal Subjects (2015) (0)
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. (2014) (0)
Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance Managing Dyslipidemia and Global Risk in Patients with Type 2 Diabetes and Insulin Resistance (2005) (0)
patients The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic (2011) (0)
Lipidomic and Proteomic Predictors of Drastic Reductions of HDL in the ACCORD Lipid Trial (2017) (0)
Basis for Dietary Treatment Participants (2005) (0)
Pericholecystic hepatic activity in a postcholecystectomy patient. (1989) (0)
Effects of dietary fats on plasma lipoprotein metabolism. (1996) (0)
As the leading cause of death among type 2 diabetic patients , coronary heart disease is prevalent in women and younger patients (2005) (0)
Linking Clinical Care and Community Interventions in Diabetes Prevention and Management (2013) (0)
Abstract 484: Apolipoprotein (a) Isoform Size Regulates Both the Production and Clearance of Circulating Lipoprotein (a) (2019) (0)
Diabetes and Dislipidemia (2018) (0)
Abstract 16398: Effect of CETP Inhibition With Anacetrapib on VLDL Triglyceride and Plasma ApoC-II, ApoC-III and ApoE Metabolism (2016) (0)
Increase in apoliporotein-A2 Levels is associated with lower cardiovascular risk in the accord lipid trial. (2017) (0)
Reduction in the risk of MACE with apabetalone in patients with recent acute coronary syndrome and diabetes according to NAFLD fibrosis score: exploratory analysis of the BETonMACE trial (2021) (0)
Age-Related Effects of Genetic Variation on Lipid Levels: The Columbia (2013) (0)
Lipoprotein metabolism in cholesteryl ester storage disease evidence that apolipoprotein b production is regulated by endogenous cholesterol synthesis (1985) (0)
Abstract: 1450 USE OF COMBINED LIPID LOWERING AND GLUCOSE LOWERING THERAPY IN DIABETES MELLITUS. (2009) (0)
The Effects of Diets on Plasma Lipids and Lipoprotein Phospholipids in Man (1989) (0)
THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL (2022) (0)
Diabetes Mellitus and Vascular Disease Risk (2000) (0)
Abstract 25: Inhibition of VLDL Assembly by Apolipoprotein B Antisense Oligonucleotides Stimulates Autophagy (2012) (0)
Hypertriglyceridemia and Atherosclerosis (1998) (0)
Hepatocytes Deficient in Nuclear Envelope Protein Lamina-associated Polypeptide 1 are an Ideal Mammalian System to Study Intranuclear Lipid Droplets (2022) (0)
Results from the ACCORD Lipid Study (2010) (0)
Abstract 329: Mechanism by Which Anacetrapib Lowers Plasma Lipoprotein (a) Concentration (2012) (0)
Abstract 20194: DGAT1 Deficiency Decreases Heart PPAR Expression and Causes Hypertrophy (2010) (0)
1.P.267 LPL-93G promoter mutation influences both baseline plasma triglycerides and postprandial response in black and hispanics (1997) (0)
An ARC light on lipid metabolism (2006) (0)
EFFICACY AND SAFETY OF ALIROCUMAB STRATIFIED BY AGE IN PHASE 3 TRIALS (2016) (0)
Reply: Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes. (2020) (0)
Meet the Expert Sessions (2017) (0)
Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid LevelsA Randomized Clinical Trial (2014) (0)
The n-3 fatty acid, docosahexaenoic acid, stimulates the secretion of apo B-100-containing lipoproteins from HepG2 cells: further evidence for a critical role of newly synthesized triglyceride (1994) (0)
HYPERTRIGLYCERIDEMIA AND ATHEROSCLEROSIS. AUTHOR'S REPLY (1998) (0)
Faculty Opinions recommendation of From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. (2010) (0)
Abstract 21171: Combinatorial Aso-Mediated Knockdown of ApoB and DGAT2 Inhibits Both VLDL Secretion and High Fat Diet Induced Hepatic Steatosis (2017) (0)
Apoprotein B: quality control early and late in the secretory pathway for this atherogenic protein (2012) (0)
RATIONALE AND DESIGN OF THE BALANCE STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF OLEZARSEN IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (2023) (0)
Relationship of Plasma ApolipoproteinC3 with Plasma Lipoprotein(a) (2021) (0)
Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion. (2022) (0)
LOWER ON-TREATMENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL IS ASSOCIATED WITH LOWER CARDIOVASCULAR RISK IN WOMEN: ANALYSES FROM THE ODYSSEY TRIALS OF ALIROCUMAB VERSUS CONTROL (2017) (0)
Low HDL cholesterol: what are the prospects of increasing it? (1995) (0)
DB111506 1680..1690 (2012) (0)
Abstract 21310: ApoCIII RX19 Mutation Lowers the Production of ApoCIII and Increases the Clearance of VLDL-TG (2017) (0)
Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes (2020) (0)
Combination therapy of hyperlipidemia (2006) (0)
Abstract 628: Hepatic Insulin Signaling Regulates ApoA-I Gene Expression Through the Type I Deiodinase. (2014) (0)
Faculty Opinions recommendation of Extended-release niacin or ezetimibe and carotid intima-media thickness. (2010) (0)
Abstract 634: Treatment with Mipomersen Reduces Levels of ApoB-Containing Lipoproteins by Increasing Fractional Removal of VLDL and LDL-apoB Without Reducing VLDL-apob Secretion (2014) (0)
Inverse Relationship Between Major Adverse Cardiovascular Events and non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in Phase 3 Trials of Alirocumab (2016) (0)
HDAC inhibition and Niemann-Pick Disease Normalization of Hepatic Homeostasis in the Npc1 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat (2016) (0)
Author response for "Potential contribution of haemoconcentration to changes in lipid parameters with empagliflozin in patients with type 2 diabetes mellitus – a post hoc analysis of pooled data from four phase III randomized clinical trials" (2021) (0)
Faculty Opinions recommendation of Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. (2008) (0)
Abstract 15710: Impact of Age on the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia (2017) (0)
In Memoriam: Dr German A. Camejo (1936-2021). (2022) (0)
Complex regulation of fatty liver disease. (2022) (0)
THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL (2020) (0)
Treatment of severe hypertriglyceridaemia--authors' reply. (2014) (0)
Correction: Personalized glucose forecasting for type 2 diabetes using data assimilation (2021) (0)
Pemafibrate improves triglyceride metabolism markers in a European population on background statin therapy (2020) (0)
P4608BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial (2019) (0)
Lipidomic and proteomic predictors of drastic reductions of HDL in the accord lipid trial. (2017) (0)
Loss of function of either LAP1 or torsina, nuclear membrane associated proteins, causes inhibition of VLDL secretion and severe steatohepatitis in chow fed mice (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Henry N Ginsberg?

Henry N Ginsberg is affiliated with the following schools:

Henry N Ginsberg's Academic­Influence.com Rankings

Henry N Ginsberg's Degrees

Why Is Henry N Ginsberg Influential?

Henry N Ginsberg's Published Works

Published Works

What Schools Are Affiliated With Henry N Ginsberg?

Henry N Ginsberg's AcademicInfluence.com Rankings